HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for PDS Biotechnology (NASDAQ:PDSB) and maintained a price target of $21.
October 24, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for PDS Biotechnology, maintaining a price target of $21, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $21 price target by a reputable analyst suggests a positive outlook for PDS Biotechnology. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100